Related Experiment Video
Updated: Aug 5, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention in Hutchinson-Gilford Progeria
Luciano De Simone1, Serena Chiellino1, Gaia Spaziani1
1Paediatric Cardiology, "Meyer" Children's Hospital, University of Florence, Viale Pieraccini, 24, 50139 Florence, Italy.
Insights
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic condition. This case report details successful percutaneous coronary intervention for severe coronary artery obstruction in a teen with HGPS.
Area of Science:
- Cardiology
- Genetics
- Pediatrics
Background:
- Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by LMNA gene mutations, leading to progerin accumulation and premature aging phenotypes, including early cardiovascular disease.
- Cardiovascular complications, such as atherosclerosis and myocardial infarction, are the primary cause of mortality in HGPS patients, significantly reducing life expectancy.
Observation:
- A 14-year-old Chinese boy with HGPS presented with precordial pain, tachycardia, and severe hypertension.
- ECG revealed sinus tachycardia, left ventricular hypertrophy, and ischemic changes. Echocardiography showed preserved left ventricular function with concentric hypertrophy and mitral insufficiency.
- Elevated high-sensitivity troponin T confirmed Non-ST-Elevation Myocardial Infarction (NSTEMI). Coronary CT angiography identified severe left main coronary artery obstruction.
Findings:
- Coronary angiography revealed chronic total occlusion of the left main coronary artery and severe stenosis of the right coronary artery.
- Successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation in the right coronary artery restored left coronary artery perfusion.
- The patient was initiated on dual antiplatelet therapy and antihypertensive medications.
Implications:
- This case highlights the feasibility and positive outcomes of urgent PCI in managing acute coronary syndromes in young HGPS patients.
- Aggressive cardiovascular risk management, including timely revascularization, may improve outcomes and prolong life in individuals with HGPS.
- Further research into the specific cardiovascular manifestations and optimal management strategies for HGPS is warranted.
Abstract:
Hutchinson-Gilford progeria syndrome is an extremely rare genetic disease caused by a de novo mutation in the LMNA gene, leading to an accumulation of a form of Lamin A, called Progerin, which results in a typical phenotype and a marked decrease in life expectancy, due to early atherosclerosis and cardiovascular disease. We report the case of a fourteen-year-old Chinese boy with Hutchinson-Gilford progeria syndrome admitted to the emergency room because of precordial pain. Physical examination showed tachycardia 130 beats/min and arterial hypertension: 170/120 mmHg, normal respiratory rate, no neurological impairment; ECG evidenced sinus tachycardia, left ventricular hypertrophy, horizontal ST-segment depression in I, aVL, II, III, aVF leads, and V4-V6 and ST-segment elevation in aVR and V1 leads. Echocardiography highlighted preserved global left ventricular function with concentric hypertrophy, altered diastolic flow pattern, mitral valve insufficiency, and minimal aortic regurgitation. Blood tests evidenced an increase in high-sensitivity troponin T level (335 pg/mL). NSTEMI diagnosis was performed, and the patient was admitted to the intensive care unit. A coronary CT angiography showed a severe obstruction of the common trunk of the left coronary artery, for which an urgent percutaneous coronary intervention (PCI) was proposed. A selective coronary angiography imaged complete chronic occlusion of the left main coronary artery as well as severe stenosis at the origin of a very enlarged right coronary artery that vascularized the left coronary artery through collaterals. Afterwards, the right coronary artery was probed using an Amplatz right (AR1) guiding catheter, through which a large 3.5 mm drug-eluting coronary stent (Xience Sierra, Abbott, Abbott Park, IL, USA) was implanted. At the end of the procedure, no residual stenosis was imaged and improved vascularization of the left coronary artery distribution segments was observed. Dual antiplatelet therapy (DAPT) consisting of aspirin (75 mg daily) and clopidogrel (37.5 mg daily) and anti-hypertensive therapy were started. At the one-year follow-up, the patient had not reported any occurrence of anginal chest pain.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome I: Introduction

